

Five-year Efficacy and Safety of TiNO-Coated Stents Versus Drug-Eluting Stents in Acute Coronary Syndrome. A meta-analysis.

Frederic C. Daoud¹, Bogdan Catargi¹, Pasi P. Karjalainen², Edouard Gerbaud^{3,4,*}

1 Endocrinology-Metabolic Diseases, Hôpital Saint-André, Bordeaux University, 33000 Bordeaux, France; frederic.daoud-pineau@chu-bordeaux.fr (F.D.); bogdan.catargi@chu-bordeaux.fr (B.C.)

2 Cardiac Unit, Heart and Lung Center, Helsinki University Hospital, Helsinki University, 00280 Helsinki, Finland; pasi.karjalainen@hus.fi (P.K.)

3 Cardiology Intensive Care Unit and Interventional Cardiology, Hôpital Cardiologique du Haut-Lévêque, 33604 Pessac, France; edouard.gerbaud@chu-bordeaux.fr (E.G.)

4 Bordeaux Cardio-Thoracic Research Centre, U1045, Bordeaux University, 33076 Bordeaux, France;

* Correspondence: edouard.gerbaud@chu-bordeaux.fr; Tel.: +33-524-549-188; Fax: +33-557-636-316

Abstract: (1) Background: Percutaneous Coronary Interventions (PCI) in patients with acute coronary syndrome (ACS) are performed with titanium-nitride-oxide-coated stents (TiNOS) or drug-eluting stents (DES). This prospective systematic literature review (SLR) of prospective, randomized, controlled trials (RCTs) showed TiNOS is non-inferior to DES in major adverse cardiac events (MACE) rates and presents a lower risk of recurrent myocardial infarction (MI) at 1-year follow-up. (2) Methods: The previously described SLR and meta-analysis protocol, per PRISMA, Cochrane methods, and GRADE, applied here to 5-year follow-up outcomes. (3) Results: Three RCTs were eligible, comprising 1,620 patients with TiNOS vs. 1,123 with DES. The pooled risk ratios (RRs) and 95% confidence intervals were: MACE 0.82 [0.68, 0.99], MI 0.58 [0.44, 0.78], cardiac death (CD) 0.46 [0.28, 0.76], ischemia-driven target lesion re-vascularization (TLR) 1.03 [0.79, 1.33], probable or definite stent thrombosis (ST) 0.32 [0.21, 0.59], and all-cause mortality (TD) 0.84 [0.63, 1.12]. Evidence certainty was high in MACE, CD, MI, and ST. Certainty was moderate in TLR and TD. (4) Conclusions: TiNOS in ACS at 5-year follow-up appears safer than DES and equally efficacious. Stratified pooled outcomes by clinical presentation would facilitate clinical validity benchmarking and generalization to target populations.

Keywords: acute coronary syndrome; non-drug-eluting titanium-nitride-oxide coated stents (TiNOS); drug-eluting stents; 5-year follow-up; safety; efficacy; systematic literature review; meta-analysis.

1. Introduction

Acute Coronary Syndrome (ACS) designates sudden myocardial ischemia. It comprises three clinical presentations: ST-segment elevation myocardial infarction (STEMI), non-ST-segment elevated myocardial infarction (NSTEMI), and unstable angina pectoris (UAP) [1]. A previous prospective Systematic Literature Review (SLR) and meta-analysis of prospective Randomized Controlled Trials (RCT) compared the 1-year follow-up clinical outcomes after Percutaneous Coronary Interventions (PCI) using non-drug-eluting Titanium-Nitride-Oxide-coated Stents (TiNOS) to treat patients with ACS [2]. The pooled Risk Ratios (RRs) showed that TiNOS was non-inferior to DES in terms of device-oriented Major Adverse Cardiac Events (MACE) rates and presented a lower risk of recurrent myocardial infarction (MI) at 1-year follow-up.

2. Materials and Methods

This SLR was conducted according to the previous prospective protocol (PROSPERO CRD4201809062) that planned 5-year follow-up outcomes analysis upon patient follow-up completion [3].

The PICO framework was used to define the research question [4]. The SLR was conducted according to the principles described in the Cochrane Handbook and the “Preferred Reporting Items for Systematic Reviews and Meta-Analyses” (PRISMA), and certainty of evidence was assessed according to the “Grading of Recommendations Assessment, Development, and Evaluation” (GRADE) [5-12]. The primary endpoint was device-oriented Major Adverse Cardiac Events (MACE). The secondary endpoints were Cardiac Death (CD), recurrent non-fatal Myocardial Infarction (MI), ischemia-driven Target Lesion Revascularization (TLR), Probable or definite Stent Thrombosis (ST), and all-cause mortality (“Total Death” TD). The endpoint definitions were those of the Academic Research Consortium (ARC-2) [13]. The detailed SLR and meta-analytic methods applied with 5-year outcomes were similar to those used with 1-year outcomes and previously published, except for the updates below [2,3].

F.D. and B.C. were the primary reviewers of 5-year outcomes, E.G. adjudicated disagreements, and P.K. obtained checked data in case of uncertainty.

The 5-year follow-up outcomes meta-analysis was computed in the 2023 versions of the same software packages as used with 1-year follow-up: RevMan, Harbord tests in STATA (version 17, StataCorp LP, College Station, TX, USA) using the metan and metabias packages, and GRADE analysis was performed in GRADEpro GDT software 2023 online (<https://gradepro.org>) [14,15]. Pubmed, Scopus, the Cochrane Library, and Web of Science (WoS) electronic databases were queried on July 5, 2023, with the same search string as previously [2]. The interpretation of the string by each database’s search engine is in Appendix A.

To avoid deriving conclusions about patients with chronic coronary syndrome (CCS) based on data from patients presenting with ACS, RCT eligibility was narrowed down to trials that either included patients with ACS only or included a mix of patients with ACS and CCS providing baseline and outcomes data in ACS and CCS were reported separately.

To improve the clinical intuitiveness of pooled RR imprecision rating, GRADE's 2011 guideline 6 was replaced by the minimally contextualized approach (guidance 34, 2022) [11,12]. An outcome's pooled RR was defined as imprecise if its 95% Confidence interval (CI) crossed threshold lines of appreciable harm, benefit, or futility, depending on the situation. The lower and upper RR thresholds were 0.9 and symmetrically 1.11 (i.e., 1/0.9). A relative risk reduction (RRR) of 10%, the "futility threshold" (lower threshold RR = 1 - RRR) in the Cochrane review of DES vs. BMS in ACS defined the thresholds [16]. In MACE and TLR, where DES was assumed to be superior to TiNOS, the RR of events in TiNOS over DES was tested for non-inferiority, and the CI was rated seriously imprecise if it crossed the upper threshold. Safety outcomes RRs (CD, MI, TD, ST) underwent a two-sided superiority test with the usual null hypothesis of no difference between the event rates of the compared treatments. A significant RR's CI was rated seriously imprecise if it crossed the nearest threshold. Non-significant RR CIs crossing one or both thresholds were rated seriously imprecise.

3. Results

3.1. Study Identification and Selection

Ninety-four records were identified, and nine publications with first-hand data about three RCTs were found eligible for pooling after selection (PRISMA flowchart in Figure 1) [5]. The 49 excluded records did not meet the PICO specifications or were review articles. One RCT comparing TiNOS to zotarolimus-eluting stents included 53% with CCS and 47% with ACS, but the study was excluded from the pooled analysis because it did not stratify the data [17,18].

3.2. Individual Study Characteristics

Table 1 summarizes the characteristics of the eligible RCTs and the re-reported raw data. The overall numbers and rates of patients lost to follow-up were 4.63% (67/1620) in the TiNOS arm and 4.36% (49/1123) in the DES arm. The pooled distribution of clinical presentation

ions was NSTEMI 48.2%, STEMI 43.2%, and UAP 8.6%.

The previously reported number of patients by clinical presentation was inconsistent with the total sample size in the baseline characteristics of TIDES-ACS [19]. The authors provided the following *corrigendum* via P.K.: the need for: The number of patients with UAP is 87 in the TiNOS arm and 37 in the DES arm, not 126 and 61, respectively.

3.3. Individual Study Risk of Bias

The Cochrane instrument was used to rate individual study 5-year follow-up risk of bias. The only consistent risk of bias across the eligible RCTs was the operators' knowledge of the stents they used (Figure 2).

3.4. Publication Bias Risk

The 5-year cumulative MACE RR funnel plot (Figure 3) detected no risk of publication bias, and the Harbord test ($p = 0.08$) detected no small-study effect.

3.5. Pooled Cumulative Outcomes

Figures 4 through 9 display the stratified pooled RRs of cumulative MACE, CD, MI, TLR, ST, and TD at 5-year follow-up. The pooled RRs of MI, CD, and ST rates show a significantly lower event rate with TiNOS than with DES. The pooled RRs of TLR and MACE rates show TiNOS non-inferiority compared with DES, although the MACE rate with TiNOS is significantly lower than with DES.

3.6. Sensitivity Analysis

The sensitivity analysis shows the impact on the pooled 5-year RRs of withdrawing one RCT at a time (Table 2). The pooled RR of all endpoints except MACE and CD are robust to sensitivity analysis. The GRADE rating shows high certainty levels with MACE, MI, and ST and moderate levels with TLR, CD, and TD.

3.7. GRADE certainty of evidence

The GRADE rating (Table 3) shows high certainty levels with MACE, CD, MI, probable or definite ST, and moderate levels with TLR and TD.

4. Discussion

4.1. Summary of the Results

The pooled analysis shows TiNOS' non-inferiority at 5-year follow-up in MACE and superiority in MI, CD, and probable or definite ST, with a high level of certainty. It also shows the non-inferiority of TiNOS in TLR at a 5-year follow-up compared to a significantly higher rate of events than with DES at a 1-year follow-up, with a moderate certainty level due to the limited number of observations. TD's RR is non-significant, but the certainty level is moderate for the same reasons as with TLR.

The increase in cumulative events in the two compared arms from one to five-year follow-ups and the updated precision grading method contribute to the increased certainty of outcomes, although RR estimates of some outcomes still have limited precision [12]. An extended follow-up of the patients beyond five years, if possible, would help identify further changes in all outcome variables, including TLR.

Overall, 5-year results show the long-term superior safety of TiNOS over DES in ACS with a high certainty level. The evidence also shows a progressive efficacy shift with the TLR rate that was significantly higher in TiNOS vs. DES at 1-year follow-up and reached non-inferiority at 5-year follow-up, although the number of observations remains insufficient for the level of evidence to become high. Extended follow-ups beyond five years should be monitored to check whether the shift continues over time.

The low rate of patients lost to follow-up in each RCT contributed to the continued low risk of bias at 5-year follow-up.

4.2. Clinical Validity

Assessing the clinical validity of the pooled RCTs requires checking that the 5-year MACE, CD, MI, TLR, probable or definite ST, and TD rates in ACS with TiNOS, EES, and PES are consistent with benchmark rates reported in larger samples of patients presenting with STEMI, NSTEMI, and UAP respectively. A PubMed and Cochrane database search for RCTs or me-ta-analyses of RCTs with those

5-year outcomes in ACS, STEMI, NSTEMI, or UAP returned no evidence with TiNOS but two meta-analyses comparing DES to BMS.

One individual patient data meta-analysis (IPDM) pooled data from 14 RCTs comparing DES vs. BMS in ACS [25]. Results were stratified outcome ratios up to 5-year follow-up in 34.5% of patients with CCS and 65.5% of patients with ACS. In the ACS subgroup, 7,739 patients were assigned to DES vs. 6,889 to BMS. The source publications of the included studies were reviewed, and ACS clinical presentations, DES types, outcomes definitions, sample sizes, and follow-up durations were checked [26-41]. None of the RCTs provide validation benchmarks for the DES arm.

One Cochrane review pooled 25 RCTs comparing the outcomes of DES vs. BMS in ACS [16]. The source publications were checked using the same methods as the IPDM [42-67]. Overall, 6,916 patients were treated with DES vs. 5,640 with BMS. A single RCT included patients with NSTEMI treated with EES, but the follow-up duration was only two years [57]. Another RCT included patients with STEMI treated with EES and reported outcomes at 5-year follow-up [42]. Another RCT included patients with STEMI treated with stainless-steel paclitaxel-eluting stents (PES) or BMS and reported outcomes at 5-year follow-up [63]. The latter two RCTs were the Cochrane review's potential contribution to the validation benchmarks of the DES arm.

This meta-analysis comparing outcomes at five years with TiNOS vs. DES in ACS is the first of its kind. Therefore, clinical validation will require pooling additional future evidence to compare each stent and each clinical presentation with the corresponding benchmarks.

4.2. Generalization of the Results

Generalizing the results of this meta-analysis to a population is possible, either if the pooled study sample and the target population share comparable pre-PCI baseline characteristics or if the meta-analytic results can be standardized proportionately to the target population's baseline characteristics. ACS covers the diversity of clinical presentations in emergency coronary care. Several epidemiological surveys have consistently shown that the incidence rate of STEMI decreases with age. In contrast, the incidence rate of NSTEMI increases with equal rates around 65 years of age, women present more frequently with NSTEMI or UAP than STEMI, and patients with STEMI are more often smokers than patients with NSTEMI [68-72]. Therefore, PCI outcomes at 5-year follow-up in any study should logically be associated with those base-line characteristics and other factors such as emergency care availability. A panel of epidemiological surveys on ACS hospital admissions and reperfusion rates shows significant differences in STEMI, NSTEMI, and UAP proportions across the sampled populations [68,69,72-76]. These differences show the difficulty of directly applying the outcomes of three pooled RCTs of this me-ta-analysis to populations with a different case mix. Reporting the pooled RRs stratified by clinical presentation can facilitate generalization to diverse populations through standardization.

5. Conclusions

The pooled outcomes at a five-year follow-up show that titani-um-nitride-oxide-coated stents are safer than drug-eluting stents in patients with acute coronary syndrome. The risk of cardiac death, myocardial infarction, and stent thrombosis is significantly lower with titanium-nitride-oxide-coated stents than with paclitaxel or everolimus-eluting metallic stents, with a high certainty level. The two stents display similar efficacy with non-significantly different target lesion revascularization rates with

a moderate certainty level. All-cause mortality rates are not significantly different with an intermediate certainty level. Overall, the rates of device-oriented major adverse cardiac events are no significantly difference with a high certainty level. These pooled results are the first of their kind. Reporting relative risks stratified by clinical presentation would facilitate the clinical validation with external benchmarks and the generalization of the pooled results to patient populations with different proportions of acute coronary clinical presentations.

Note: The ineligible records are references [2,16,66,77-122].

Supplementary Materials: Not applicable.

Author Contributions: F.D.: Designed the review protocol. F.D. and B.N.: Main reviewers and analysts. E.G.: Third reviewer and adjudicated disagreements. P.K.: Provided additional information about the methods of the individual trials and confirmed the number of patients lost to follow-up. All authors participated in finalizing the manuscript. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: Not applicable. This work is a review of peer-reviewed articles available in Pubmed, Scopus, the Cochrane Library, and Web of Science.

Conflicts of Interest: The authors declare no conflict of interest.

Appendix A. Detailed Search Strings in Each Database

Pubmed search string: ((bioactive OR (Titanium AND nitride AND oxide) OR TiNO OR TNO OR BAS) AND stent) AND (DES OR (drug AND eluting AND stent)) AND (RCT OR ((randomised OR randomised) AND controlled AND trial))

(“bioactivate”[All Fields] OR “bioactivated”[All Fields] OR “bioactivates”[All Fields] OR
“bioactivating”[All Fields] OR “bioactivation”[All Fields] OR “bioacti-vations”[All Fields] OR
“bioactive”[All Fields] OR “bioactives”[All Fields] OR “bioactivities”[All Fields] OR
“bioactivity”[All Fields] OR ((“titanium”[MeSH Terms] OR “titanium”[All Fields] OR
“titaniums”[All Fields]) AND (“nitridated”[All Fields] OR “nitridation”[All Fields] OR “nitride”[All
Fields] OR “nitrided”[All Fields] OR “nitrides”[All Fields] OR “nitriding”[All Fields] OR
“nitridized”[All Fields]) AND (“oxidability”[All Fields] OR “oxidable”[All Fields] OR “oxidant
s”[All Fields] OR “oxidants”[Pharmacological Action] OR “oxidants”[MeSH Terms] OR
“oxidants”[All Fields] OR “oxidant”[All Fields] OR “oxidate”[All Fields] OR “oxidated”[All Fields]
OR “oxidates”[All Fields] OR “oxidating”[All Fields] OR “oxidation”[All Fields] OR
“oxidations”[All Fields] OR “oxidative”[All Fields] OR “oxidatively”[All Fields] OR
“oxidatives”[All Fields] OR “oxide s”[All Fields] OR “oxides”[MeSH Terms] OR “oxides”[All

Fields] OR “oxide”[All Fields] OR “oxidic”[All Fields] OR “oxiding”[All Fields] OR “oxidisability”[All Fields] OR “oxidisable”[All Fields] OR “oxidisation”[All Fields] OR “oxidise”[All Fields] OR “oxidised”[All Fields] OR “oxidiser”[All Fields] OR “oxidisers”[All Fields] OR “oxidises”[All Fields] OR “oxidising”[All Fields] OR “oxidization”[All Fields] OR “oxidize”[All Fields] OR “oxidized”[All Fields] OR “oxidizer”[All Fields] OR “oxidizers”[All Fields] OR “oxidizes”[All Fields] OR “oxidizing”[All Fields])) OR “TiNO”[All Fields] OR “TNO”[All Fields] OR “BAS”[All Fields] AND (“stent s”[All Fields] OR “stentings”[All Fields] OR “stents”[MeSH Terms] OR “stents”[All Fields] OR “stent”[All Fields] OR “stented”[All Fields] OR “stenting”[All Fields]) AND (“DES”[All Fields] OR (“drug”[All Fields] AND (“elutable”[All Fields] OR “elutant”[All Fields] OR “elute”[All Fields] OR “eluted”[All Fields] OR “elutent”[All Fields] OR “eluter”[All Fields] OR “eluters”[All Fields] OR “elutes”[All Fields] OR “eluting”[All Fields] OR “elution”[All Fields] OR “elutions”[All Fields]) AND (“stent s”[All Fields] OR “stentings”[All Fields] OR “stents”[MeSH Terms] OR “stents”[All Fields] OR “stent”[All Fields] OR “stented”[All Fields] OR “stenting”[All Fields])))) AND (“RCT”[All Fields] OR ((“random allocation”[MeSH Terms] OR (“random”[All Fields] AND “allocation”[All Fields]) OR “random allocation”[All Fields] OR “random”[All Fields] OR “randomization”[All Fields] OR “randomized”[All Fields] OR “randomisation”[All Fields] OR “randomisations”[All Fields] OR “randomise”[All Fields] OR “randomised”[All Fields] OR “randomising”[All Fields] OR “randomizations”[All Fields] OR “randomize”[All Fields] OR “randomizes”[All Fields] OR “randomizing”[All Fields] OR “randomness”[All Fields] OR “randoms”[All Fields] OR (“random allocation”[MeSH Terms] OR (“random”[All Fields] AND “allocation”[All Fields]) OR “random allocation”[All Fields] OR “random”[All Fields] OR “randomization”[All Fields] OR “randomized”[All Fields] OR “randomisation”[All Fields] OR “randomisations”[All Fields] OR “randomise”[All Fields] OR “randomised”[All Fields] OR “randomising”[All Fields] OR “randomizations”[All Fields] OR “randomize”[All Fields] OR “randomizes”[All Fields] OR “randomizing”[All Fields] OR “randomness”[All Fields] OR “randoms”[All Fields])))) AND “controlled”[All Fields] AND (“clinical trials as topic”[MeSH Terms] OR (“clinical”[All Fields] AND “trials”[All Fields] AND “topic”[All Fields]) OR “clinical trials as topic”[All Fields] OR “trial”[All Fields] OR “trial s”[All Fields] OR “trialed”[All Fields] OR “trailing”[All Fields] OR “trials”[All Fields]))

Translations

bioactive: “bioactivate”[All Fields] OR “bioactivated”[All Fields] OR “bioacti-vates”[All Fields] OR “bioactivating”[All Fields] OR “bioactivation”[All Fields] OR “bioactivations”[All Fields] OR “bioactive”[All Fields] OR “bioactives”[All Fields] OR “bioactivities”[All Fields] OR “bioactivity”[All Fields]

Titanium: “titanium”[MeSH Terms] OR “titanium”[All Fields] OR “titani-um’s”[All Fields] OR “titaniums”[All Fields]

nitride: “nitridated”[All Fields] OR “nitridation”[All Fields] OR “nitride”[All Fields] OR “nitrided”[All Fields] OR “nitrides”[All Fields] OR “nitriding”[All Fields] OR “nitridized”[All Fields]

oxide: “oxidability”[All Fields] OR “oxidable”[All Fields] OR “oxidant’s”[All Fields] OR “oxidants”[Pharmacological Action] OR “oxidants”[MeSH Terms] OR “oxidants”[All Fields] OR “oxidant”[All Fields] OR “oxidate”[All Fields] OR “oxi-dated”[All Fields] OR “oxidates”[All Fields] OR “oxidating”[All Fields] OR “oxi-dation”[All Fields] OR “oxidations”[All Fields] OR “oxidative”[All Fields] OR “oxidatively”[All Fields] OR “oxidatives”[All Fields] OR “oxide’s”[All Fields] OR “oxides”[MeSH Terms] OR “oxides”[All Fields] OR “oxide”[All Fields] OR “oxi-dic”[All

Fields] OR “oxidizing”[All Fields] OR “oxidisability”[All Fields] OR “oxi-disable”[All Fields] OR “oxidisation”[All Fields] OR “oxidise”[All Fields] OR “oxi-dised”[All Fields] OR “oxidiser”[All Fields] OR “oxidisers”[All Fields] OR “oxidis-es”[All Fields] OR “oxidising”[All Fields] OR “oxidization”[All Fields] OR “oxi-dize”[All Fields] OR “oxidized”[All Fields] OR “oxidizer”[All Fields] OR “oxidiz-ers”[All Fields] OR “oxidizes”[All Fields] OR “oxidizing”[All Fields]

stent: “stent’s”[All Fields] OR “stentings”[All Fields] OR “stents”[MeSH Terms] OR “stents”[All Fields] OR “stent”[All Fields] OR “stented”[All Fields] OR “stenting”[All Fields]

eluting: “elutable”[All Fields] OR “elutant”[All Fields] OR “elute”[All Fields] OR “eluted”[All Fields] OR “elutent”[All Fields] OR “eluter”[All Fields] OR “eluters”[All Fields] OR “elutes”[All Fields] OR “eluting”[All Fields] OR “elu-tion”[All Fields] OR “elutions”[All Fields]

stent: “stent’s”[All Fields] OR “stentings”[All Fields] OR “stents”[MeSH Terms] OR “stents”[All Fields] OR “stent”[All Fields] OR “stented”[All Fields] OR “stenting”[All Fields]

randomized: “random allocation”[MeSH Terms] OR (“random”[All Fields] AND “allocation”[All Fields]) OR “random allocation”[All Fields] OR “random”[All Fields] OR “randomization”[All Fields] OR “randomized”[All Fields] OR “randomisation”[All Fields] OR “randomisations”[All Fields] OR “randomise”[All Fields] OR “randomised”[All Fields] OR “randomising”[All Fields] OR “randomi-zations”[All Fields] OR “randomize”[All Fields] OR “randomizes”[All Fields] OR “randomizing”[All Fields] OR “randomness”[All Fields] OR “randoms”[All Fields]

randomised: “random allocation”[MeSH Terms] OR (“random”[All Fields] AND “allocation”[All Fields]) OR “random allocation”[All Fields] OR “random”[All Fields] OR “randomization”[All Fields] OR “randomized”[All Fields] OR “randomisation”[All Fields] OR “randomisations”[All Fields] OR “randomise”[All Fields] OR “randomised”[All Fields] OR “randomising”[All Fields] OR “randomizations”[All Fields] OR “randomize”[All Fields] OR “randomizes”[All Fields] OR “randomizing”[All Fields] OR “randomness”[All Fields] OR “randoms”[All Fields]

trial: “clinical trials as topic”[MeSH Terms] OR (“clinical”[All Fields] AND “trials”[All Fields] AND “topic”[All Fields]) OR “clinical trials as topic”[All Fields] OR “trial”[All Fields] OR “trial’s”[All Fields] OR “trialed”[All Fields] OR “trial-ing”[All Fields] OR “trials”[All Fields]

Cochrane database search string: ((bioactive OR (Titanium AND nitride AND oxide) OR TiNO OR TNO OR BAS) AND stent) AND (DES OR (drug AND eluting AND stent)) AND (RCT OR ((randomised OR randomised) AND controlled AND trial)).

Web of Science search string: (((bioactive OR (Titanium AND nitride AND oxide) OR TiNO OR TNO OR BAS) AND stent) AND (DES OR (drug AND eluting AND stent)) AND (RCT OR ((randomised OR randomised) AND controlled AND trial)))

Embase search string: (((bioactive OR (Titanium AND nitride AND oxide) OR TiNO OR TNO OR BAS) AND stent) AND (DES OR (drug AND eluting AND stent)) AND (RCT OR ((randomised OR randomised) AND controlled AND trial)))/br.

References

1. Bhatt, D.L.; Lopes, R.D.; Harrington, R.A. Diagnosis and Treatment of Acute Coronary Syndromes: A Review. JAMA 2022, 327, 662-675, doi:10.1001/jama.2022.0358.

2. Daoud, F.C.; Létinier, L.; Moore, N.; Coste, P.; Karjalainen, P.P. Efficacy and Safety of TiNO-Coated Stents versus Drug-Eluting Stents in Acute Coronary Syndrome: Systematic Literature Review and Meta-Analysis. *Biomedicines* 2022, 10, doi:10.3390/biomedicines10123159.
3. https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=90622, accessed on June 04 2023.
4. Huang, X.; Lin, J.; Demner-Fushman, D. Evaluation of PICO as a knowledge representation for clinical questions. *AMIA Annu Symp Proc* 2006, 2006, 359-363.
5. Liberati, A.; Altman, D.G.; Tetzlaff, J.; Mulrow, C.; Gotzsche, P.C.; Ioannidis, J.P.; Clarke, M.; Devereaux, P.J.; Kleijnen, J.; Moher, D. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. *BMJ* 2009, 339, b2700, doi:10.1136/bmj.b2700.
6. Higgins, J.P.T.G., S. (Eds.). Cochrane Handbook for Systematic Reviews of Interventions. Available online: [www.https://handbook-5-1.cochrane.org](https://handbook-5-1.cochrane.org), version 5.1.0 updated March 2011 (accessed on 8 March 2018).
7. Guyatt, G.H.; Oxman, A.D.; Vist, G.E.; Kunz, R.; Falck-Ytter, Y.; Alonso-Coello, P.; Schunemann, H.J.; Group, G.W. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. *BMJ* 2008, 336, 924-926, doi:10.1136/bmj.39489.470347.AD.
8. Guyatt, G.H.; Oxman, A.D.; Montori, V.; Vist, G.; Kunz, R.; Brozek, J.; Alonso-Coello, P.; Djulbegovic, B.; Atkins, D.; Falck-Ytter, Y.; et al. GRADE guidelines: 5. Rating the quality of evidence--publication bias. *J Clin Epidemiol* 2011, 64, 1277-1282, doi:10.1016/j.jclinepi.2011.01.011.
9. Guyatt, G.H.; Oxman, A.D.; Kunz, R.; Woodcock, J.; Brozek, J.; Helfand, M.; Alonso-Coello, P.; Falck-Ytter, Y.; Jaeschke, R.; Vist, G.; et al. GRADE guidelines: 8. Rating the quality of evidence--indirectness. *J Clin Epidemiol* 2011, 64, 1303-1310, doi:10.1016/j.jclinepi.2011.04.014.
10. Schünemann, H.B., J.; Guyatt, G.; Oxman, A. (Eds.) GRADE Handbook for Grading Quality of Evidence and Strength of Recommendations. Updated October 2013. The GRADE Working Group, 2013. Available online: Guide-lineddevelopment.org/handbook (accessed on 8 March 2018).
11. Guyatt, G.H.; Oxman, A.D.; Kunz, R.; Brozek, J.; Alonso-Coello, P.; Rind, D.; Devereaux, P.J.; Montori, V.M.; Freyschuss, B.; Vist, G.; et al. GRADE guidelines 6. Rating the quality of evidence--imprecision. *J Clin Epidemiol* 2011, 64, 1283-1293, doi:10.1016/j.jclinepi.2011.01.012.
12. Zeng, L.; Brignardello-Petersen, R.; Hultcrantz, M.; Mustafa, R.A.; Murad, M.H.; Iorio, A.; Traversy, G.; Akl, E.A.; Mayer, M.; Schunemann, H.J.; et al. GRADE Guidance 34: update on rating imprecision using a minimally contextualized approach. *J Clin Epidemiol* 2022, 150, 216-224, doi:10.1016/j.jclinepi.2022.07.014.
13. Garcia-Garcia, H.M.; McFadden, E.P.; Farb, A.; Mehran, R.; Stone, G.W.; Spertus, J.; Onuma, Y.; Morel, M.A.; van Es, G.A.; Zuckerman, B.; et al. Standardized End Point Definitions for Coronary Intervention Trials: The Academic Research Consortium-2 Consensus Document. *Eur Heart J* 2018, 39, 2192-2207, doi:10.1093/eurheartj/ehy223.
14. Harbord, R.M.; Egger, M.; Sterne, J.A. A modified test for small-study effects in meta-analyses of controlled trials with binary endpoints. *Stat Med* 2006, 25, 3443-3457, doi:10.1002/sim.2380.

15. GRADEpro GDT: GRADEpro Guideline Development Tool [Software]. McMaster University, D.b.E.P., Inc.). Available online: <https://gdt.gradepro.org> (accessed on 11 July 2023).
16. Feinberg, J.; Nielsen, E.E.; Greenhalgh, J.; Hounsome, J.; Sethi, N.J.; Safi, S.; Gluud, C.; Jakobsen, J.C. Drug-eluting stents versus bare-metal stents for acute coronary syndrome. Cochrane Database of Systematic Reviews 2017, doi:10.1002/14651858.CD012481.pub2.
17. Pilgrim, T.; Räber, L.; Limacher, A.; Löffel, L.; Wenaweser, P.; Cook, S.; Stauffer, J.C.; Togni, M.; Vogel, R.; Garachemani, A.; et al. Comparison of titanium-nitride-oxide-coated stents with zotarolimus-eluting stents for coronary revascularization a randomized controlled trial. JACC Cardiovasc Interv 2011, 4, 672-682, doi:10.1016/j.jcin.2011.02.017.
18. Pilgrim, T.; Räber, L.; Limacher, A.; Wenaweser, P.; Cook, S.; Stauffer, J.C.; Garachemani, A.; Moschovitis, A.; Meier, B.; Jüni, P.; et al. Five-year results of a randomised comparison of titanium-nitride-oxide-coated stents with zotarolimus-eluting stents for coronary revascularisation. EuroIntervention 2015, 10, 1284-1287, doi:10.4244/eijy15m01_04.
19. Tonino, P.A.L.; Pijls, N.H.J.; Collet, C.; Nammas, W.; Van der Heyden, J.; Romppanen, H.; Kervinen, K.; Airaksinen, J.K.E.; Sia, J.; Lalmand, J.; et al. Titanium-Nitride-Oxide-Coated Versus Everolimus-Eluting Stents in Acute Coronary Syndrome: The Randomized TIDES-ACS Trial. JACC Cardiovasc Interv 2020, 13, 1697-1705, doi:10.1016/j.jcin.2020.04.021.
20. Karjalainen, P.P.; Ylitalo, A.; Niemelä, M.; Kervinen, K.; Mäkkilä, T.; Pietilä, M.; Sia, J.; Tuomainen, P.; Nyman, K.; Airaksinen, J. Titanium-nitride-oxide coated stents versus paclitaxel-eluting stents in acute myocardial infarction: a 12-months follow-up report from the TITAX AMI trial. EuroIntervention 2008, 4, 234-241, doi:10.4244/EIJV4I2A42.
21. Tuomainen, P.O.; Ylitalo, A.; Niemelä, M.; Kervinen, K.; Pietilä, M.; Sia, J.; Nyman, K.; Nammas, W.; Airaksinen, K.E.; Karjalainen, P.P. Five-year clinical outcome of titanium-nitride-oxide-coated bioactive stents versus paclitaxel-eluting stents in patients with acute myocardial infarction: long-term follow-up from the TITAX AMI trial. Int J Cardiol 2013, 168, 1214-1219, doi:10.1016/j.ijcard.2012.11.060.
22. Karjalainen, P.P.; Niemelä, M.; Airaksinen, J.K.E.; Rivero-Crespo, F.; Romppanen, H.; Sia, J.; Lalmand, J.; De Bruyne, B.; DeBelder, A.; Carlier, M.; et al. A prospective randomised comparison of titanium-nitride-oxide-coated bioactive stents with everolimus-eluting stents in acute coronary syndrome: The BASE-ACS trial. EuroIntervention 2012, 8, 306-315, doi:10.4244/EIJV8I3A49.
23. Karjalainen, P.P.; Nammas, W.; Ylitalo, A.; de Bruyne, B.; Lalmand, J.; de Belder, A.; Rivero-Crespo, F.; Kervinen, K.; Airaksinen, J.K.E. Long-term clinical outcome of titanium-nitride-oxide-coated stents versus everolimus-eluting stents in acute coronary syndrome: Final report of the BASE ACS trial. Int. J. Cardiol. 2016, 222, 275-280, doi:10.1016/j.ijcard.2016.07.267.
24. Bouisset, F.; Sia, J.; Mizukami, T.; Karjalainen, P.P.; Tonino, P.A.L.; Pijls, N.H.J.; Van der Heyden, J.; Romppanen, H.; Kervinen, K.; Airaksinen, J.K.E.; et al. Titanium-Nitride-Oxide-Coated vs Everolimus-Eluting Stents in Acute Coronary Syndrome: 5-Year Clinical Outcomes of the TIDES-ACS Randomized Clinical Trial. JAMA cardiology 2023, doi:10.1001/jamacardio.2023.1373.
25. Piccolo, R.; Bonaa, K.; Efthimiou, O.; Varenne, O.; Baldo, A.; Urban, P.; Kaiser, C.; de Belder, A.; Lemos, P.; Wilsgaard, T.; et al. Individual Patient Data Meta-analysis of Drug-eluting

Versus Bare-metal Stents for Percutaneous Coronary Intervention in Chronic Versus Acute Coronary Syndromes. Am J Cardiol 2022, 182, 8-16, doi:10.1016/j.amjcard.2022.07.035.

26. Tsuchida, K.; Piek, J.J.; Neumann, F.J.; van der Giessen, W.J.; Wiemer, M.; Zeiher, A.M.; Grube, E.; Haase, J.; Thuesen, L.; Hamm, C.W.; et al. One-year results of a durable polymer everolimus-eluting stent in de novo coronary narrowings (The SPIRIT FIRST Trial). EuroIntervention 2005, 1, 266-272.
27. Fajadet, J.; Wijns, W.; Laarman, G.J.; Kuck, K.H.; Ormiston, J.; Munzel, T.; Popma, J.J.; Fitzgerald, P.J.; Bonan, R.; Kuntz, R.E.; et al. Randomized, double-blind, multicenter study of the Endeavor zotarolimus-eluting phosphorylcholine-encapsulated stent for treatment of native coronary artery lesions: clinical and angiographic results of the ENDEAVOR II trial. Circulation 2006, 114, 798-806, doi:10.1161/CIRCULATIONAHA.105.591206.
28. Eisenstein, E.L.; Wijns, W.; Fajadet, J.; Mauri, L.; Edwards, R.; Cowper, P.A.; Kong, D.F.; Anstrom, K.J. Long-term clinical and economic analysis of the Endeavor drug-eluting stent versus the Driver bare-metal stent: 4-year results from the ENDEAVOR II trial (Randomized Controlled Trial to Evaluate the Safety and Efficacy of the Medtronic AVE ABT-578 Eluting Driver Coronary Stent in De Novo Native Coronary Artery Lesions). JACC Cardiovasc Interv 2009, 2, 1178-1187, doi:10.1016/j.jcin.2009.10.011.
29. Lemos, P.A.; Moulin, B.; Perin, M.A.; Oliveira, L.A.; Arruda, J.A.; Lima, V.C.; Lima, A.A.; Caramori, P.R.; Medeiros, C.R.; Barbosa, M.R.; et al. Late clinical outcomes after implantation of drug-eluting stents coated with biodegradable polymers: 3-year follow-up of the PAINT randomised trial. EuroIntervention 2012, 8, 117-119, doi:10.4244/EIJV8I1A18.
30. Marchini, J.F.; Gomes, W.F.; Moulin, B.; Perin, M.A.; Oliveira, L.A.; Arruda, J.A.; Lima, V.C.; Lima, A.A.; Caramori, P.R.; Medeiros, C.R.; et al. Very late outcomes of drug-eluting stents coated with biodegradable polymers: insights from the 5-year follow-up of the randomized PAINT trial. Cardiovasc Diagn Ther 2014, 4, 480-486, doi:10.3978/j.issn.2223-3652.2014.12.05.
31. Kaiser, C.; Galatius, S.; Erne, P.; Eberli, F.; Alber, H.; Rickli, H.; Pedrazzini, G.; Hornig, B.; Bertel, O.; Bonetti, P.; et al. Drug-eluting versus bare-metal stents in large coronary arteries. N Engl J Med 2010, 363, 2310-2319, doi:10.1056/NEJMoa1009406.
32. Reifart, N.; Hauptmann, K.E.; Rabe, A.; Enayat, D.; Giokoglu, K. Short and long term comparison (24 months) of an alternative sirolimus-coated stent with bioabsorbable polymer and a bare metal stent of similar design in chronic coronary occlusions: the CORACTO trial. EuroIntervention 2010, 6, 356-360, doi:10.4244/EIJV6I3A59.
33. Mehilli, J.; Pache, J.; Abdel-Wahab, M.; Schulz, S.; Byrne, R.A.; Tiroch, K.; Hausleiter, J.; Seyfarth, M.; Ott, I.; Ibrahim, T.; et al. Drug-eluting versus bare-metal stents in saphenous vein graft lesions (ISAR-CABG): a randomised controlled superiority trial. Lancet 2011, 378, 1071-1078, doi:10.1016/S0140-6736(11)61255-5.
34. Valgimigli, M.; Tebaldi, M.; Borghesi, M.; Vranckx, P.; Campo, G.; Tumscitz, C.; Cangiano, E.; Minarelli, M.; Scalzone, A.; Cavazza, C.; et al. Two-year outcomes after first- or second-generation drug-eluting or bare-metal stent implantation in all-comer patients undergoing percutaneous coronary intervention: a pre-specified analysis from the PRODIGY study (PROlonging Dual Antiplatelet Treatment After Grading stent-induced Intimal hyperplasia studY). JACC Cardiovasc Interv 2014, 7, 20-28, doi:10.1016/j.jcin.2013.09.008.

35. Ribeiro, E.E.; Campos, C.M.; Ribeiro, H.B.; Lopes, A.C.; Esper, R.B.; Meirelles, G.X.; Perin, M.A.; Abizaid, A.; Lemos, P.A. First-in-man randomised comparison of a novel sirolimus-eluting stent with abluminal biodegradable polymer and thin-strut cobalt-chromium alloy: INSPIRON-I trial. *EuroIntervention* 2014, 9, 1380-1384, doi:10.4244/EIJV9I12A234.
36. de Belder, A.; de la Torre Hernandez, J.M.; Lopez-Palop, R.; O'Kane, P.; Hernandez Hernandez, F.; Strange, J.; Gimeno, F.; Cotton, J.; Diaz Fernandez, J.F.; Carrillo Saez, P.; et al. A prospective randomized trial of everolimus-eluting stents versus bare-metal stents in octogenarians: the XIMA Trial (Xience or Vision Stents for the Management of Angina in the Elderly). *J Am Coll Cardiol* 2014, 63, 1371-1375, doi:10.1016/j.jacc.2013.10.053.
37. Kaiser, C.; Galatius, S.; Jeger, R.; Gilgen, N.; Skov Jensen, J.; Naber, C.; Alber, H.; Wanitschek, M.; Eberli, F.; Kurz, D.J.; et al. Long-term efficacy and safety of biodegradable-polymer biolimus-eluting stents: main results of the Basel Stent Kosten-Effektivitats Trial-PROspective Validation Examination II (BASKET-PROVE II), a randomized, controlled non-inferiority 2-year outcome trial. *Circulation* 2015, 131, 74-81, doi:10.1161/CIRCULATIONAHA.114.013520.
38. Urban, P.; Meredith, I.T.; Abizaid, A.; Pocock, S.J.; Carrie, D.; Naber, C.; Lipiecki, J.; Richardt, G.; Iniguez, A.; Brunel, P.; et al. Polymer-free Drug-Coated Coronary Stents in Patients at High Bleeding Risk. *N Engl J Med* 2015, 373, 2038-2047, doi:10.1056/NEJMoa1503943.
39. Valgimigli, M.; Patialiakas, A.; Thury, A.; McFadden, E.; Colangelo, S.; Campo, G.; Tebaldi, M.; Ungi, I.; Tondi, S.; Roffi, M.; et al. Zotarolimus-eluting versus bare-metal stents in uncertain drug-eluting stent candidates. *J Am Coll Cardiol* 2015, 65, 805-815, doi:10.1016/j.jacc.2014.11.053.
40. Bonaa, K.H.; Mannsverk, J.; Wiseth, R.; Aaberge, L.; Myreng, Y.; Nygard, O.; Nilsen, D.W.; Klow, N.E.; Uchto, M.; Trovik, T.; et al. Drug-Eluting or Bare-Metal Stents for Coronary Artery Disease. *N Engl J Med* 2016, 375, 1242-1252, doi:10.1056/NEJMoa1607991.
41. Varenne, O.; Cook, S.; Sideris, G.; Kedev, S.; Cuisset, T.; Carrie, D.; Hovasse, T.; Garot, P.; El Mahmoud, R.; Spaulding, C.; et al. Drug-eluting stents in elderly patients with coronary artery disease (SENIOR): a randomised single-blind trial. *Lancet* 2018, 391, 41-50, doi:10.1016/S0140-6736(17)32713-7.
42. Sabate, M.; Brugaletta, S.; Cequier, A.; Iniguez, A.; Serra, A.; Jimenez-Quevedo, P.; Mainar, V.; Campo, G.; Tespili, M.; den Heijer, P.; et al. Clinical outcomes in patients with ST-segment elevation myocardial infarction treated with everolimus-eluting stents versus bare-metal stents (EXAMINATION): 5-year results of a randomised trial. *Lancet* 2016, 387, 357-366, doi:10.1016/S0140-6736(15)00548-6.
43. Darkahian, M.; Peighambari, M.M. Comparison of the mid-term outcome between drug-eluting stent and bare metal stent implantation in patients undergoing primary PCI in Rajaie Heart Center January 2012- April 2013. *Iranian Heart Journal* 2014, 15, 12-19.
44. Belkacemi, A.; Agostoni, P.; Nathoe, H.M.; Voskuil, M.; Shao, C.; Van Belle, E.; Wildbergh, T.; Politi, L.; Doevedans, P.A.; Sangiorgi, G.M.; et al. First results of the DEB-AMI (drug eluting balloon in acute ST-segment elevation myocardial infarction) trial: a multicenter randomized comparison of drug-eluting balloon plus bare-metal stent versus bare-metal stent versus drug-eluting stent in primary percutaneous coronary intervention with 6-month angiographic, intravascular, functional, and clinical outcomes. *J Am Coll Cardiol* 2012, 59, 2327-2337, doi:10.1016/j.jacc.2012.02.027.

45. Pitt, J.; Reeve, M.; Whitlam, H.; Pulikal, G.; Ment, N.; El Gaylani, N. Drug eluting versus bare metal stents in acute ST elevation myocardial infarction (DEVINE) - a randomised control trial. European heart journal 2007, 28 (Abstract Supplement), 206.
46. Steinwender, C.; Hofmann, R.; Kypta, A.; Kammler, J.; Kerschner, K.; Grund, M.; Sihorsch, K.; Gabriel, C.; Leisch, F. In-stent restenosis in bare metal stents versus sirolimus-eluting stents after primary coronary intervention for acute myocardial infarction and subsequent transcoronary transplantation of autologous stem cells. Clin Cardiol 2008, 31, 356-359, doi:10.1002/clc.20235.
47. Strozzi, M.; Anic, D. Comparison of stent graft, sirolimus stent, and bare metal stent implanted in patients with acute coronary syndrome: clinical and angiographic follow-up. Croat Med J 2007, 48, 348-352.
48. Chechi, T.; Vittori, G.; Biondi Zoccai, G.G.; Vecchio, S.; Falchetti, E.; Spaziani, G.; Baldereschi, G.; Giglioli, C.; Valente, S.; Margheri, M. Single-center randomized evaluation of paclitaxel-eluting versus conventional stent in acute myocardial infarction (SELECTION). J Interv Cardiol 2007, 20, 282-291, doi:10.1111/j.1540-8183.2007.00270.x.
49. Gao, H.; Yan, H.B.; Zhu, X.L.; Li, N.; Ai, H.; Wang, J.; Li, S.Y.; Yang, D. Firebird sirolimus eluting stent versus bare mental stent in patients with ST-segment elevation myocardial infarction. Chin Med J (Engl) 2007, 120, 863-867.
50. Konig, A.; Leibig, M.; Rieber, J.; Schiele, T.M.; Theisen, K.; Siebert, U.; Gothe, R.M.; Klauss, V. Randomized comparison of dexamethasone-eluting stents with bare metal stent implantation in patients with acute coronary syndrome: serial angiographic and sonographic analysis. Am Heart J 2007, 153, 979 e971-978, doi:10.1016/j.ahj.2007.03.032.
51. Sabate, M.; Cequier, A.; Iniguez, A.; Serra, A.; Hernandez-Antolin, R.; Mainar, V.; Valgimigli, M.; Tespili, M.; den Heijer, P.; Bethencourt, A.; et al. Everolimus-eluting stent versus bare-metal stent in ST-segment elevation myocardial infarction (EXAMINATION): 1 year results of a randomised controlled trial. Lancet 2012, 380, 1482-1490, doi:10.1016/S0140-6736(12)61223-9.
52. Tierala, I.; Syvanne, M.; Kupari, M. Randomised comparison of a paclitaxel-eluting and a bare metal stent in STEMI-PCI Am. J. Cardiol. 2006, TCT abstracts ;98 (Meeting abstract), 78M.
53. Sanchez, P.L.; Gimeno, F.; Ancillo, P.; Sanz, J.J.; Alonso-Briales, J.H.; Bosa, F.; Santos, I.; Sanchis, J.; Bethencourt, A.; Lopez-Messa, J.; et al. Role of the paclitaxel-eluting stent and tirofiban in patients with ST-elevation myocardial infarction undergoing postfibrinolysis angioplasty: the GRACIA-3 randomized clinical trial. Circ Cardiovasc Interv 2010, 3, 297-307, doi:10.1161/CIRCINTERVENTIONS.109.920868.
54. Ribamar Costa, J., Jr.; Abizaid, A.; Sousa, A.; Siqueira, D.; Chamie, D.; Feres, F.; Costa, R.; Staico, R.; Maldonado, G.; Centemero, M.; et al. Serial greyscale and radiofrequency intravascular ultrasound assessment of plaque modification and vessel geometry at proximal and distal edges of bare metal and first-generation drug-eluting stents. EuroIntervention 2012, 8, 225-234, doi:10.4244/EIJV8I2A36.
55. Diaz de la Llera, L.S.; Ballesteros, S.; Nevado, J.; Fernandez, M.; Villa, M.; Sanchez, A.; Retegui, G.; Garcia, D.; Martinez, A. Sirolimus-eluting stents compared with standard stents in the treatment of patients with primary angioplasty. Am Heart J 2007, 154, 164 e161-166, doi:10.1016/j.ahj.2007.04.007.

56. Guagliumi, G.; Sirbu, V.; Bezerra, H.; Biondi-Zocca, G.; Fiocca, L.; Musumeci, G.; Matiashvili, A.; Lortkipanidze, N.; Tahara, S.; Valsecchi, O.; et al. Strut coverage and vessel wall response to zotarolimus-eluting and bare-metal stents implanted in patients with ST-segment elevation myocardial infarction: the OCTAMI (Optical Coherence Tomography in Acute Myocardial Infarction) Study. *JACC Cardiovasc Interv* 2010, 3, 680-687, doi:10.1016/j.jcin.2010.04.005.
57. Remkes, W.S.; Badings, E.A.; Hermanides, R.S.; Rasoul, S.; Dambrink, J.E.; Koopmans, P.C.; The, S.H.; Ottervanger, J.P.; Gosselink, A.T.; Hoornje, J.C.; et al. Randomised comparison of drug-eluting versus bare-metal stenting in patients with non-ST elevation myocardial infarction. *Open Heart* 2016, 3, e000455, doi:10.1136/openhrt-2016-000455.
58. Stone, G.W.; Witzenbichler, B.; Guagliumi, G.; Peruga, J.Z.; Brodie, B.R.; Dudek, D.; Kornowski, R.; Hartmann, F.; Gersh, B.J.; Pocock, S.J.; et al. Heparin plus a glycoprotein IIb/IIIa inhibitor versus bivalirudin monotherapy and paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction (HORIZONS-AMI): final 3-year results from a multicentre, randomised controlled trial. *Lancet* 2011, 377, 2193-2204, doi:10.1016/S0140-6736(11)60764-2.
59. Valgimigli, M.; Campo, G.; Gambetti, S.; Bolognese, L.; Ribichini, F.; Colangelo, S.; de Cesare, N.; Rodriguez, A.E.; Russo, F.; Moreno, R.; et al. Three-year follow-up of the MULTICentre evaluation of Single high-dose Bolus TiRofiban versus Abciximab with Sirolimus-eluting STEnt or Bare-Metal Stent in Acute Myocardial Infarction StudY (MULTISTRATEGY). *Int J Cardiol* 2013, 165, 134-141, doi:10.1016/j.ijcard.2011.07.106.
60. Di Lorenzo, E.; De Luca, G.; Sauro, R.; Varricchio, A.; Capasso, M.; Lanzillo, T.; Manganelli, F.; Mariello, C.; Siano, F.; Pagliuca, M.R.; et al. The PASEO (PaclitAxel or Sirolimus-Eluting Stent Versus Bare Metal Stent in Primary Angioplasty) Randomized Trial. *JACC Cardiovasc Interv* 2009, 2, 515-523, doi:10.1016/j.jcin.2009.03.012.
61. Spaulding, C.; Teiger, E.; Commeau, P.; Varenne, O.; Bramucci, E.; Slama, M.; Beatt, K.; Tirouvanziam, A.; Polonski, L.; Stella, P.R.; et al. Four-year follow-up of TYPHOON (trial to assess the use of the CYPHer sirolimus-eluting coronary stent in acute myocardial infarction treated with BallOON angioplasty). *JACC Cardiovasc Interv* 2011, 4, 14-23, doi:10.1016/j.jcin.2010.10.007.
62. Magro, M.; Raber, L.; Heg, D.; Taniwaki, M.; Kelbaek, H.; Ostojic, M.; Baumbach, A.; Tuller, D.; von Birgelen, C.; Roffi, M.; et al. The MI SYNTAX score for risk stratification in patients undergoing primary percutaneous coronary intervention for treatment of acute myocardial infarction: a substudy of the COMFORTABLE AMI trial. *Int J Cardiol* 2014, 175, 314-322, doi:10.1016/j.ijcard.2014.05.029.
63. Vink, M.A.; Dirksen, M.T.; Suttorp, M.J.; Tijssen, J.G.; van Etten, J.; Patterson, M.S.; Slagboom, T.; Kiemeneij, F.; Laarman, G.J. 5-year follow-up after primary percutaneous coronary intervention with a paclitaxel-eluting stent versus a bare-metal stent in acute ST-segment elevation myocardial infarction: a follow-up study of the PASSION (Paclitaxel-Eluting Versus Conventional Stent in Myocardial Infarction with ST-Segment Elevation) trial. *JACC Cardiovasc Interv* 2011, 4, 24-29, doi:10.1016/j.jcin.2010.11.003.
64. Musto, C.; Fiorilli, R.; De Felice, F.; Patti, G.; Nazzaro, M.S.; Scappaticci, M.; Bernardi, L.; Violini, R. Long-term outcome of sirolimus-eluting vs bare-metal stent in the setting of acute myocardial infarction: 5-year results of the SESAMI trial. *Int J Cardiol* 2013, 166, 399-403, doi:10.1016/j.ijcard.2011.10.117.

65. Wijnbergen, I.; Tijssen, J.; Brueren, G.; Peels, K.; van Dantzig, J.M.; Veer, M.V.; Koolen, J.J.; Michels, R.; Pijls, N.H. Long-term comparison of sirolimus-eluting and bare-metal stents in ST-segment elevation myocardial infarction. *Coron Artery Dis* 2014, 25, 378-383, doi:10.1097/MCA.0000000000000118.
66. Atary, J.Z.; van der Hoeven, B.L.; Liem, S.S.; Jukema, J.W.; van der Bom, J.G.; Atsma, D.E.; Bootsma, M.; Zeppenfeld, K.; van der Wall, E.E.; Schalij, M.J. Three-year outcome of sirolimus-eluting versus bare-metal stents for the treatment of ST-segment elevation myocardial infarction (from the MISSION! Intervention Study). *Am J Cardiol* 2010, 106, 4-12, doi:10.1016/j.amjcard.2010.02.005.
67. Holmvang, L.; Kelbaek, H.; Kaltoft, A.; Thuesen, L.; Lassen, J.F.; Clemmensen, P.; Klovgaard, L.; Engstrom, T.; Botker, H.E.; Saunamaki, K.; et al. Long-term outcome after drug-eluting versus bare-metal stent implantation in patients with ST-segment elevation myocardial infarction: 5 years follow-up from the randomized DEDICATION trial (Drug Elution and Distal Protection in Acute Myocardial Infarction). *JACC Cardiovasc Interv* 2013, 6, 548-553, doi:10.1016/j.jcin.2012.12.129.
68. (NICOR.), B.C.S.T.N.I.f.C.O.R. Myocardial Ischaemia National Audit Project (MINAP): 2021 summary report. https://www.nicor.org.uk/wp-content/uploads/2021/10/MINAP-Domain-Report_2021_FINAL.pdf 2021.
69. Neumann, J.T.; Gossling, A.; Sorensen, N.A.; Blankenberg, S.; Magnussen, C.; Westermann, D. Temporal trends in incidence and outcome of acute coronary syndrome. *Clin Res Cardiol* 2020, 109, 1186-1192, doi:10.1007/s00392-020-01612-1.
70. Erol, M.K.; Kayikcioglu, M.; Kilickap, M.; Arin, C.B.; Kurt, I.H.; Aktas, I.; Gunes, Y.; Ozkan, E.; Sen, T.; Ince, O.; et al. Baseline clinical characteristics and patient profile of the TURKMI registry: Results of a nation-wide acute myocardial infarction registry in Turkey. *Anatol J Cardiol* 2020, 24, 43-53, doi:10.14744/AnatolJCardiol.2020.69696.
71. Ralapanawa, U.; Kumarasiri, P.V.R.; Jayawickreme, K.P.; Kumarihamy, P.; Wijeratne, Y.; Ekanayake, M.; Dissanayake, C. Epidemiology and risk factors of patients with types of acute coronary syndrome presenting to a tertiary care hospital in Sri Lanka. *BMC Cardiovasc Disord* 2019, 19, 229, doi:10.1186/s12872-019-1217-x.
72. N'Guetta, R.; Yao, H.; Ekou, A.; N'Cho-Mottoh, M.P.; Angoran, I.; Tano, M.; Konin, C.; Coulibaly, I.; Anzouan-Kacou, J.B.; Seka, R.; et al. [Prevalence and characteristics of acute coronary syndromes in a sub-Saharan Africa population]. *Ann Cardiol Angeiol (Paris)* 2016, 65, 59-63, doi:10.1016/j.ancard.2016.01.001.
73. Yeh, R.W.; Sidney, S.; Chandra, M.; Sorel, M.; Selby, J.V.; Go, A.S. Population trends in the incidence and outcomes of acute myocardial infarction. *N Engl J Med* 2010, 362, 2155-2165, doi:10.1056/NEJMoa0908610.
74. McManus, D.D.; Gore, J.; Yarzebski, J.; Spencer, F.; Lessard, D.; Goldberg, R.J. Recent trends in the incidence, treatment, and outcomes of patients with STEMI and NSTEMI. *Am J Med* 2011, 124, 40-47, doi:10.1016/j.amjmed.2010.07.023.
75. Negi, P.C.; Merwaha, R.; Panday, D.; Chauhan, V.; Guleri, R. Multicenter HP ACS Registry. *Indian Heart J* 2016, 68, 118-127, doi:10.1016/j.ihj.2015.07.027.

76. Inohara, T.; Kohsaka, S.; Yamaji, K.; Iida, O.; Shinke, T.; Sakakura, K.; Ishii, H.; Amano, T.; Ikari, Y. Use of Thrombus Aspiration for Patients With Acute Coronary Syndrome: Insights From the Nationwide J-PCI Registry. *J Am Heart Assoc* 2022, 11, e025728, doi:10.1161/JAHA.122.025728.
77. Windecker, S.; Simon, R.; Lins, M.; Klauss, V.; Eberli, F.R.; Roffi, M.; Pedrazzini, G.; Moccetti, T.; Wenaweser, P.; Togni, M.; et al. Randomized comparison of a titanium-nitride-oxide-coated stent with a stainless steel stent for coronary revascularization - The TiNOX trial. *Circulation* 2005, 111, 2617-2622, doi:10.1161/CIRCULATIONAHA.104.486647.
78. Grube, E.; Buellesfeld, L. BioMatrix Biolimus A9-eluting coronary stent: a next-generation drug-eluting stent for coronary artery disease. *Expert review of medical devices* 2006, 3, 731-741, doi:10.1586/17434440.3.6.731.
79. Wu, P.; Grainger, D.W. - Drug/device combinations for local drug therapies and infection prophylaxis. 2006, - 27, - 2467.
80. Coolong, A.; Kuntz, R.E. Understanding the drug-eluting stent trials. *Am J Cardiol* 2007, 100, 17k-24k, doi:10.1016/j.amjcard.2007.06.004.
81. Konorza, T.F.M. Prospective, multi-center randomized trial to compare the implantation of a titanium-nitride-oxide coated stent with a paclitaxel stent in patients with acute myocardial infarction. *Herz* 2007, 32, 513, doi:10.1007/s00059-007-3036-6.
82. Karjalainen, P.P.; Ylitalo, A.; Niemelä, M.; Kervinen, K.; Mäkkilä, T.; Pietilä, M.; Sia, J.; Tuomainen, P.; Nyman, K.; Airaksinen, K.E.J. Two-year follow-up after percutaneous coronary intervention with titanium-nitride-oxide-coated stents versus paclitaxel-eluting stents in acute myocardial infarction. *Ann. Med.* 2009, 41, 599-607, doi:10.1080/07853890903111018.
83. Sant'Anna, F.M.; Batista, L.A.; Brito, M.B.; Menezes, S.; Ventura, F.M.; Buczynski, L.; Barrozo, C.A.M. Randomized comparison of percutaneous coronary intervention with titanium-nitride-oxide-coated stents versus stainless steel stents in patients with coronary artery disease: RIO trial. *Rev. Bras. Cardiologia Invasiva* 2009, 17, 69-75.
84. Dibra, A.; Tiroch, K.; Schulz, S.; Kelbæk, H.; Spaulding, C.; Laarman, G.J.; Valgimigli, M.; Di Lorenzo, E.; Kaiser, C.; Tierala, I.; et al. Drug-eluting stents in acute myocardial infarction: Updated meta-analysis of randomized trials. *Clin. Res. Cardiol.* 2010, 99, 345-357, doi:10.1007/s00392-010-0133-y.
85. Konorza, T.F.M. Randomized comparison of titanium-nitride-oxide coated stents with zotarolimus-eluting stents for coronary revascularisation. *Herz* 2010, 35, 364, doi:10.1007/s00059-010-3359-6.
86. Moschovitis, A.; Simon, R.; Seidenstucker, A.; Klauss, V.; Baylacher, M.; Luscher, T.F.; Moccetti, T.; Windecker, S.; Meier, B.; Hess, O.M. - Randomised comparison of titanium-nitride-oxide coated stents with bare metal stents: five year follow-up of the TiNOX trial. 2010, - 6, - 68.
87. Karjalainen, P.; Nammas, W. Bioactive stents for percutaneous coronary intervention: A new forerunner on the track. *Intervent. Cardiol.* 2011, 3, 527-529, doi:10.2217/ica.11.61.
88. Boden, H.; van der Hoeven, B.L.; Liem, S.S.; Atary, J.Z.; Cannegieter, S.C.; Atsma, D.E.; Bootsma, M.; Jukema, J.W.; Zeppenfeld, K.; Oemrawsingh, P.V.; et al. Five-year clinical follow-up from the MISSION! Intervention Study: sirolimus-eluting stent versus bare metal stent implantation in

patients with ST-segment elevation myocardial infarction, a randomised controlled trial. EuroIntervention 2012, 7, 1021-1029, doi:10.4244/EIJV7I9A164.

89. Lehtinen, T.; Airaksinen, K.E.; Ylitalo, A.; Karjalainen, P.P. Stent strut coverage of titanium-nitride-oxide coated stent compared to paclitaxel-eluting stent in acute myocardial infarction: TITAX-OCT study. The international journal of cardiovascular imaging 2012, 28, 1859-1866, doi:10.1007/s10554-012-0032-6.
90. Tuomainen, P.O.; Ylitalo, A.; Niemelä, M.; Kervinen, K.; Pietilä, M.; Sia, J.; Nyman, K.; Nammas, W.; Airaksinen, K.E.J.; Karjalainen, P.P. Gender-based analysis of the 3-year outcome of bioactive stents versus paclitaxel-eluting stents in patients with acute myocardial infarction: An insight from the TITAX-AMI trial. J. Invasive Cardiol. 2012, 24, 104-108.
91. De Luca, G.; Dirksen, M.T.; Spaulding, C.; Kelbk, H.; Schalij, M.; Thuesen, L.; Van der Hoeven, B.; Vink, M.A.; Kaiser, C.; Musto, C.; et al. - Impact of Diabetes on Long-Term Outcome After Primary Angioplasty. 2013, - 36, - 1025.
92. Karjalainen, P. Neointimal coverage and vasodilator response to titanium-nitride-oxide- coated bioactive stents and everolimus-eluting stents in patients with acute coronary syndrome: Insights from the BASE-ACS trial. Int. J. Card. Imaging 2013, 29, 1693-1703, doi:10.1007/s10554-013-0285-8.
93. Lammer, J.; Zeller, T.; Hausegger, K.A.; Schaefer, P.J.; Gschwendtner, M.; Mueller-Huelsbeck, S.; Rand, T.; Funovics, M.; Wolf, F.; Rastan, A.; et al. Heparin-bonded covered stents versus bare-metal stents for complex femoropopliteal artery lesions: The randomized VIASTAR trial (viabahn endoprosthesis with propanen bioactive surface [VIA] versus bare nitinol stent in the treatment of long lesions in superficial femoral artery occlusive disease). J. Am. Coll. Cardiol. 2013, 62, 1320-1327, doi:10.1016/j.jacc.2013.05.079.
94. Romppanen, H.; Nammas, W.; Kervinen, K.; Mikkelsson, J.; Pietilä, M.; Lalmand, J.; Rivero-Crespo, F.; Pentikäinen, M.; Tedjokusumo, P.; Karjalainen, P.P. Outcome of ST-elevation myocardial infarction versus non-ST-elevation acute coronary syndrome treated with titanium-nitride-oxide-coated versus everolimus-eluting stents: insights from the BASE-ACS trial. Minerva cardioangiologica 2013, 61, 201-209.
95. Velders, M.A.; Boden, H.; van der Hoeven, B.L.; Liem, S.S.; Atary, J.Z.; van der Wall, E.E.; Jukema, J.W.; Schalij, M.J. - Long-term outcome of second-generation everolimus-eluting stents and Endeavor zotarolimus-eluting stents in a prospective registry of ST-elevation myocardial infarction patients. 2013, - 8, - 1206.
96. Huang, Y.; Ng, H.C.A.; Ng, X.W.; Subbu, V. Drug-eluting biostable and erodible stents. J. Control. Release 2014, 193, 188-201, doi:10.1016/j.jconrel.2014.05.011.
97. López-Mínguez, J.R.; Nogales-Asensio, J.M.; Doncel-Vecino, L.J.; Merchán-Herrera, A.; Pomar-Domingo, F.; Martínez-Romero, P.; Fernández-Díaz, J.A.; Valdesuso-Aguilar, R.; Moreu-Burgos, J.; Díaz-Fernández, J. A randomized study to compare bioactive titanium stents and everolimus-eluting stents in diabetic patients (TITANIC XV): 1-year results. Revista espanola de cardiologia (English ed.) 2014, 67, 522-530, doi:10.1016/j.rec.2013.10.021.
98. Ribamar Costa, J.; Almeida, B.O.; Costa, R.; Chamié, D.; Abizaid, A.; Perin, M.; Staico, R.; Feres, F.; Siqueira, D.; Veloso, M.; et al. Comparison of drug-eluting stents with durable or

bioabsorbable polymer: Intracoronary ultrasound results of the BIOACTIVE trial. Rev. Bras. Cardiologia Invasiva 2014, 22.

99. Tuomainen, P.O.; Sia, J.; Nammas, W.; Niemelä, M.; Airaksinen, J.K.; Biancari, F.; Karjalainen, P.P. Pooled analysis of two randomized trials comparing titanium-nitride-oxide-coated stent versus drug-eluting stent in STEMI. Revista espanola de cardiologia (English ed.) 2014, 67, 531-537, doi:10.1016/j.rec.2014.01.024.
100. Bosiers, M.; Deloose, K.; Callaert, J.; Verbist, J.; Hendriks, J.; Lauwers, P.; Schroë, H.; Lansink, W.; Scheinert, D.; Schmidt, A.; et al. Superiority of stent-grafts for in-stent restenosis in the superficial femoral artery: Twelve-month results from a multicenter randomized trial. J. Endovasc. Ther. 2015, 22, 1-10, doi:10.1177/1526602814564385.
101. Chamié, D.; Almeida, B.O.; Grandi, F.; Filho, E.M.; Costa, J.R.; Costa, R.; Staico, R.; Siqueira, D.; Feres, F.; Tanajura, L.F.; et al. Vascular response after implantation of biolimus A9-eluting stent with bioabsorbable polymer and everolimus-eluting stents with durable polymer. Results of the optical coherence tomography analysis of the BIOACTIVE randomized trial. Rev. Bras. Cardiologia Invasiva 2015, 23, 28-37, doi:10.1016/j.rbc.2015.02.001.
102. Sia, J.; Nammas, W.; Niemelä, M.; Airaksinen, J.K.E.; Lalmand, J.; Laine, M.; Tedjokusumo, P.; Nyman, K.; Biancari, F.; Karjalainen, P.P. Gender-based analysis of randomized comparison of bioactive versus everolimus-eluting stents in acute coronary syndrome. J. Cardiovasc. Med. 2015, 16, 197-203, doi:10.2459/JCM.00000000000000086.
103. Karjalainen, P.P.; Airaksinen, J.K.E.; de Belder, A.; Romppanen, H.; Kervinen, K.; Sia, J.; Laine, M.; Nammas, W. Long-term outcome of early percutaneous coronary intervention in diabetic patients with acute coronary syndrome: insights from the BASE ACS trial. Ann. Med. 2016, 48, 376-383, doi:10.1080/07853890.2016.1186829.
104. Karjalainen, P.P.; Niemelä, M.; Pietilä, M.; Sia, J.; de Belder, A.; Rivero-Crespo, F.; de Bruyne, B.; Nammas, W. 4-Year outcome of bioactive stents versus everolimus-eluting stents in acute coronary syndrome. Scand. Cardiovasc. J. 2016, 50, 218-223, doi:10.1080/14017431.2016.1177198.
105. Kayssi, A.; Al-Atassi, T.; Oreopoulos, G.; Roche-Nagle, G.; Tan, K.T.; Rajan, D.K. Drug-eluting balloon angioplasty versus uncoated balloon angioplasty for peripheral arterial disease of the lower limbs. Cochrane Database of Systematic Reviews 2016, doi:10.1002/14651858.CD011319.pub2.
106. Varho, V.; Kiviniemi, T.O.; Nammas, W.; Sia, J.; Romppanen, H.; Pietilä, M.; Airaksinen, J.K.; Mikkelsson, J.; Tuomainen, P.; Perälä, A.; et al. Early vascular healing after titanium-nitride-oxide-coated stent versus platinum-chromium everolimus-eluting stent implantation in patients with acute coronary syndrome. The international journal of cardiovascular imaging 2016, 32, 1031-1039, doi:10.1007/s10554-016-0871-7.
107. Karjalainen, P.; Paana, T.; Ylitalo, A.; Sia, J.; Nammas, W. Optical coherence tomography follow-up 18 months after titanium-nitride-oxide-coated versus everolimus-eluting stent implantation in patients with acute coronary syndrome. Acta radiologica (Stockholm, Sweden : 1987) 2017, 58, 1077-1084, doi:10.1177/0284185116683573.
108. Karjalainen, P.P.; Nammas, W. Titanium-nitride-oxide-coated coronary stents: insights from the available evidence. Annals of medicine 2017, 49, 299-309, doi:10.1080/07853890.2016.1244353.

109. Karjalainen, P.P.; Niemelä, M.; Laine, M.; Airaksinen, J.K.E.; Ylitalo, A.; Nammas, W. Usefulness of Post-coronary Dilation to Prevent Recurrent Myocardial Infarction in Patients Treated With Percutaneous Coronary Intervention for Acute Coronary Syndrome (from the BASE ACS Trial). *Am. J. Cardiol.* 2017, 119, 345-350, doi:10.1016/j.amjcard.2016.09.057.
110. Nammas, W.; Airaksinen, J.K.E.; Romppanen, H.; Sia, J.; de Belder, A.; Karjalainen, P.P. Impact of Preexisting Vascular Disease on the Outcome of Patients With Acute Coronary Syndrome: Insights From the Comparison of Bioactive Stent to the Everolimus-Eluting Stent in Acute Coronary Syndrome Trial. *Angiology* 2017, 68, 513-518, doi:10.1177/0003319716664266.
111. Nammas, W.; de Belder, A.; Niemelä, M.; Sia, J.; Romppanen, H.; Laine, M.; Karjalainen, P.P. Long-term clinical outcome of elderly patients with acute coronary syndrome treated with early percutaneous coronary intervention: Insights from the BASE ACS randomized controlled trial: Bioactive versus everolimus-eluting stents in elderly patients. *Eur. J. Intern. Med.* 2017, 37, 43-48, doi:10.1016/j.ejim.2016.07.027.
112. Varho, V.; Nammas, W.; Kiviniemi, T.O.; Sia, J.; Romppanen, H.; Pietilä, M.; Airaksinen, J.K.; Karjalainen, P.P. Comparison of two different sampling intervals for optical coherence tomography evaluation of neointimal healing response after coronary stent implantation. *Int. J. Cardiol.* 2017, 227, 194-200, doi:10.1016/j.ijcard.2016.11.173.
113. Hsu, C.C.T.; Kwan, G.N.C.; Singh, D.; Rophael, J.A.; Anthony, C.; van Driel, M.L. Angioplasty versus stenting for infrapopliteal arterial lesions in chronic limb-threatening ischaemia. *Cochrane Database of Systematic Reviews* 2018, doi:10.1002/14651858.CD009195.pub2.
114. Hernandez, J.M.D.; Moreno, R.; Gonzalo, N.; Rivera, R.; Linares, J.A.; Fernandez, G.V.; Menchero, A.G.; del Blanco, B.G.; Hernandez, F.; Gonzalez, T.B.; et al. - The Pt-Cr everolimus-eluting stent with bioabsorbable polymer in the treatment of patients with acute coronary syndromes. Results from the SYNERGY ACS registry. 2019, - 20, - 710.
115. Kayssi, A.; Al-Jundi, W.; Papia, G.; Kucey, D.S.; Forbes, T.; Rajan, D.K.; Neville, R.; Dueck, A.D. Drug-eluting balloon angioplasty versus uncoated balloon angioplasty for the treatment of in-stent restenosis of the femoropopliteal arteries. *Cochrane Database of Systematic Reviews* 2019, doi:10.1002/14651858.CD012510.pub2.
116. Kuroda, K.; Otake, H.; Shinohara, M.; Kuroda, M.; Tsuda, S.; Toba, T.; Nagano, Y.; Toh, R.; Ishida, T.; Shinke, T.; et al. Effect of rosuvastatin and eicosapentaenoic acid on neoatherosclerosis: The LINK-IT Trial. *EuroIntervention* 2019, 15, E1099-E1106, doi:10.4244/EIJ-D-18-01073.
117. Collet, C.; Tonino, P.A.L.; Mizukami, T.; Pijls, N.H.J.; De Bruyne, B.; Karjalainen, P.P. Reply: The Randomized TIDES-ACS Trial. *JACC Cardiovasc. Interventions* 2020, 13, 2444-2445, doi:10.1016/j.jcin.2020.09.009.
118. Kuno, T.; Takahashi, M.; Hamaya, R. The Randomized TIDES-ACS Trial. *JACC Cardiovasc. Interventions* 2020, 13, 2444, doi:10.1016/j.jcin.2020.08.004.
119. Wardle, B.G.; Ambler, G.K.; Radwan, R.W.; Hinchliffe, R.J.; Twine, C.P. Atherectomy for peripheral arterial disease. *Cochrane Database of Systematic Reviews* 2020, doi:10.1002/14651858.CD006680.pub3.

120. Gómez-Lara, J.; Oyarzabal, L.; Brugaletta, S.; Salvatella, N.; Romaguera, R.; Roura, G.; Fuentes, L.; Pérez Fuentes, P.; Ortega-Paz, L.; Ferreiro, J.L.; et al. Coronary endothelial and microvascular function distal to polymer-free and endothelial cell-capturing drug-eluting stents. The randomized FUNCOMBO trial. Revista espanola de cardiologia (English ed.) 2021, 74, 1013-1022, doi:10.1016/j.rec.2021.01.007.

121. Gomez-Lara, J.; Oyarzabal, L.; Ortega-Paz, L.; Brugaletta, S.; Romaguera, R.; Salvatella, N.; Roura, G.; Rivero, F.; Fuentes, L.; Alfonso, F.; et al. Coronary endothelium-dependent vasomotor function after drug-eluting stent and bioresorbable scaffold implantation. J. Am. Heart Assoc. 2021, 10, doi:10.1161/JAHA.121.022123.

122. Sia, J.; Nammas, W.; Collet, C.; De Bruyne, B.; Karjalainen, P.P. Comparative study of neointimal coverage between titanium-nitric oxide-coated and everolimus-eluting stents in acute coronary syndromes. Rev. Esp. Cardiol. 2023, 76, 150-156, doi:10.1016/j.recesp.2022.05.011.

TABLES

Table 1. Eligible studies for 5-year follow-up. Baseline characteristics.

Study	Age and Prior Events		Clinical Presentation (Included and Pooled)				Procedural Data and Medication			Lost to follow-up	
	Stent	TiNOS	DES	TiNOS N incl, % pooled	DES N incl, % pooled		TiNOS	DES			
TITAX-											
AMI	Patients n	214	211				stents/culprit lesion			1.1 ± 0.3	1.1 ± 0.4
	age	64 ± 11	64 ± 11				n			18.5 ± 6.4	19.2 ± 7.2
DES = PES	prior MI	15%	9%	STEMI	83, 39%	97, 46%	TSL (mm)			42%	35%
	prior PCI	10%	5%	NSTEMI	131, 61%	114, 54%	post-dilation			99.5%	98.1%
[20,21]	prior CABG	7%	6%	UAP	0, 0%	0, 0%	procedural success			31%	65%
							DAPT 12 m				
BASE-											
ACS	Patients n	417	410				stents/culprit lesion			1.15 ± 0.38	1.14 ± 0.36
	age	63 ± 12	63 ± 12				n			20.8 ± 9.4	20.6 ± 8.2
DES = EES	prior MI	13.4%	9.8%	STEMI	162, 38.8%	159, 38.8%	TSL (mm)			42.2%	43.9%
	prior PCI	9.6%	10.5%	NSTEMI	206, 49.4%	187, 45.6%	post-dilation			0.0%	1.0%
[22,23]	prior CABG	4.8%	4.1%	UAP	49, 11.8%	64, 15.6%	stent failure				
							DAPT:				
							Aspirin: N.R. Clopidogrel: N.R.				
TIDES-											
ACS	Patients n	989	502				stents/culprit lesion			1.13 ± 0.38	1.14 ± 0.37
	age	62.7 ± 10.7.6%	62.6 ± 10.5				n			20.5 ± 7.8	20.6 ± 7.2
DES = EES	prior MI	9.0%	9.0%	STEMI	444, 44.9%	239, 47.6%	TSL (mm)			33.0%	38.0%
	prior PCI	7.0%	6.6%	NSTEMI	458, 46.3%	226, 45.8%	post-dilation			0.3%	1.0%
[19,24]	prior CABG	0.6%	1.2%	UAP	87, 8.8%	37, 7.4%	stent failure			80.3%	86.0%
							DAPT 12 m				

EES: everolimus eluting stent; PES: paclitaxel eluting stent; N.R.: not reported. DAPT: dual antiplatelet treatment; TSL: total stent length.

Table 2. Sensitivity analysis of all endpoints TiNOS vs. DES at 5-year follow-up.

M-H Fixed Effects RR and 95% CI after the Removal of:						
Endpoint	None	TITAX-AMI	TIDE	BASE-ACS	TIDES-ACS	Robustness
MACE	0.82 [0.68, 0.99]	0.88 [0.71, 1.09]	N.A.	0.82 [0.65, 1.04]	0.74 [0.58, 0.95]	No
CD	0.46 [0.28, 0.76]	0.51 [0.30, 0.89]	N.A.	0.31 [0.16, 0.61]	0.59 [0.31, 1.11]	No
MI	0.59 [0.44, 0.78]	0.61 [0.44, 0.85]	N.A.	0.60 [0.43, 0.85]	0.54 [0.37, 0.80]	Yes
TLR	1.03 [0.79, 1.33]	1.03 [0.76, 1.38]	N.A.	1.11 [0.81, 1.54]	0.94 [0.66, 1.32]	Yes
probable or definite ST	0.32 [0.19, 0.55]	0.40 [0.22, 0.73]	N.A.	0.30 [0.15, 0.58]	0.25 [0.12, 0.55]	Yes
TD	0.84 [0.63, 1.12]	0.84 [0.61, 1.16]	N.A.	0.76 [0.54, 1.08] ^c	1.03 [0.74, 1.45]	Yes

N.A.: Not applicable

Table 3. GRADE Summary of findings—TiNOS vs. DES in ACS at 5-year follow-up

Outcome	Risk of Bias	Inconsistency	Indirectness	Imprecision	Publication Bias	Certainty of Evidence
MACE	not serious	not serious	not serious	not serious ^a	none	⊕⊕⊕⊕ HIGH
CD	not serious	not serious ^c	not serious	not serious ^b	none	⊕⊕⊕⊕ HIGH
MI	not serious	not serious	not serious	not serious ^b	none	⊕⊕⊕⊕ HIGH
TLR	not serious	not serious	not serious	serious ^d	none	⊕⊕⊕□ MODERATE
probable or definite ST	not serious	not serious	not serious	not serious ^b	none	⊕⊕⊕⊕ HIGH
TD	not serious	not serious	not serious	serious ^e	none	⊕⊕⊕□ MODERATE

CI: confidence interval; RR: risk ratio

a. The CI does not cross the RR = 1.11 threshold.

b. The CI does not cross the RR = 0.9 and RR = 1.11 thresholds.

c. Although $I^2=42\%$, Q-test $p = 0.18$, the three-point estimates of RR are <1 with overlapping CIs.

d. The CI crosses the RR = 1.11 threshold.

e. The CI crosses the RR = 0.9 and RR = 1.11 thresholds.

FIGURES




Figure 1. PRISMA flowchart




Figure 2. Individual Study Risk of Bias – 5-year follow-up




Figure 3. Funnel plot – Risk of Publication Bias – 5-year cumulative MACE RR



Figure 4. Forest plot – cumulative MACE – 5-year follow-up




Figure 5. Forest plot – cumulative CD – 5-year follow-up




Figure 6. Forest plot – cumulative MI – 5-year follow-up



Figure 7. Forest plot – cumulative TLR – 5-year follow-up




Figure 8. Forest plot – cumulative ST – 5-year follow-up




Figure 9. Forest plot – cumulative TD – 5-year follow-up